Stage 4 lung cancer: choosing the first treatment
First-line treatment for stage IV non-small cell lung cancer is chosen using the cancer's molecular results, PD-L1 level, pathology and your overall condition. A targetable alteration may lead to targeted therapy. When no suitable target is found, immunotherapy alone or with chemotherapy may be considered. Symptom care starts alongside those decisions. The most useful first step is to check that the proposed treatment accounts for both your test results and how urgently the cancer needs controlling.
On this page
Understand what stage IV changes
Stage IV means the lung cancer has spread in a way that is classified as metastatic disease. Treatment usually focuses on controlling cancer across the body, easing symptoms and prolonging life. The pattern of spread still matters, particularly when only a few sites are involved.
Ask which findings establish metastatic disease and whether any uncertain lesion needs clarification. A spot on a scan can sometimes have another explanation. The team will balance the value of further testing against the need to begin treatment promptly.
Sources and references: [1]
Complete the tests that choose the first medicine
Pathology distinguishes squamous from nonsquamous disease and helps guide the chemotherapy component. Molecular testing looks for actionable changes such as EGFR, ALK, ROS1 and other targets. PD-L1 testing adds information about the potential role of checkpoint immunotherapy.
If a blood-based molecular test is negative, the team may still need tissue testing. Ask whether the sample had enough cancer material and whether the panel covered the alterations relevant to your situation. A negative result and an incomplete test should lead to different conversations.
When a targeted drug fits
For some molecular subtypes, a matched targeted drug is a usual starting point. The specific alteration, brain involvement and treatment evidence help select the medicine. Drugs directed at one EGFR alteration, for example, may not be appropriate for another.
Ask how treatment will be monitored and which adverse effects are most relevant to the proposed drug. Oral treatment still requires laboratory checks, symptom review and repeat imaging. Bring a complete list of medicines and supplements so interactions can be checked before the first prescription.
Sources and references: [1]
When immunotherapy or chemotherapy is chosen
For cancer without an actionable driver, the team considers PD-L1, histology, symptoms and fitness when choosing immunotherapy alone or a combination with chemotherapy. A high PD-L1 level can support a single-agent option in selected patients, but disease burden and the need for a response also matter.
Checkpoint therapy can cause inflammation in healthy organs. Chemotherapy brings a different pattern of side effects, including low blood counts, nausea and fatigue. Ask what the combination adds in your setting and how the team would manage a serious reaction.
Sources and references: [1]
Why radiation or a procedure may still help
Systemic treatment addresses disease throughout the body. Local treatment may be added for brain metastases, painful bone disease, bleeding, airway obstruction or another site causing a specific problem. Some patients with limited metastatic disease may also have a broader discussion about treating every known site.
Ask whether a proposed local treatment is intended to relieve a symptom, prevent an urgent complication or improve longer-term control. That purpose determines how it should be timed with systemic therapy and what benefit to expect from the procedure.
Sources and references: [1]
Make symptom relief part of the first-line plan
Pain, breathlessness, poor sleep and weight loss can interfere with treatment and daily life. Supportive or palliative care can work alongside anticancer treatment from the beginning. Report problems early, including the activities you have stopped because of symptoms.
Sudden severe breathlessness, new weakness, confusion or a seizure needs urgent assessment. A routine appointment inquiry is not the right route for an acute problem. For ongoing symptoms, ask for a written plan covering medications, nutrition support and the contact to use when the plan is not helping.
Sources and references: [1]
Agree on how the first treatment will be assessed
Ask when repeat scans are planned and which symptoms should improve if treatment is working. The team interprets imaging together with your condition and laboratory results. A single change may need context before a treatment is stopped or switched.
It also helps to discuss what comes next if control is lost: another systemic option, molecular retesting, a clinical trial or a greater emphasis on symptom care. This does not commit you to a future treatment. It gives you time to prepare for decisions while the current plan is underway.
Sources and references: [1]
What to ask a Shanghai team to review
A useful Shanghai review can focus on whether testing is complete, whether a targeted option matches the exact alteration or whether a local treatment could address a difficult symptom. Start with EastMedGo's lung cancer information and share the proposed first-line regimen.
We can help organize the records and appointment inquiry, including questions about further tests, visit requirements and coordination costs. If treatment has already started, send the drug names and dates. Keeping the treating team involved helps avoid gaps while another opinion is being arranged.
Common questions
Can stage IV lung cancer be treated with tablets?
Some molecular subtypes can be treated with oral targeted drugs. Suitability depends on a matching alteration and the clinical setting. Tablets can still have serious side effects and require monitoring; the route of administration does not determine how intensive follow-up should be.
Sources and references: [1]
Is chemotherapy always the first treatment?
No. A matched targeted medicine or an immunotherapy-based approach may be selected. Chemotherapy remains important for many patients and may be combined with these medicines in defined settings. The laboratory results and treatment goal should explain the choice.
Sources and references: [1]
Should I travel immediately to look for a newer drug?
First confirm the diagnosis, exact molecular result and current treatment recommendation. An appointment inquiry can clarify whether another center offers a relevant assessment and what information it requires. Travel timing should also account for symptoms and ongoing treatment.
Sources and references
- Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version
- Biomarker Testing for Cancer Treatment
- Liquid Biopsy: Using Tumor DNA in Blood to Aid Cancer Care
Prepared with AI assistance by EastMedGo for patients comparing treatment and care options.